71 results about "Vascular risk" patented technology

A method and apparatus for providing real-time support in interpreting a patient's ECG in order to assess the probability of perioperative cardiovascular risk associated with performing a non-cardiac surgery. The apparatus includes an acquisition unit for acquiring an ECG and a processor for determining whether the ECG has diagnostic statements of risk. From the diagnostic statements of risk, the processor determines the probability of cardiovascular risk associated with the non-cardiac surgery. The probability of cardiovascular risk is displayed on display in the form of an indicator of either major, intermediate, or minor cardiovascular risk.

The method includes acquiring a patient's ECG, determining whether the ECG exhibits diagnostic statements of cardiovascular risk, and determining the probability of cardiovascular risk based on the diagnostic statements, and displaying the determined probability of cardiovascular risk.

A statistical (a) Computer Aided Diagnostic (CAD) technique is described for symptomatic versus asymptomatic plaque automated classification of carotid ultrasound images and (b) presents a cardiovascular risk score computation. We demonstrate this for longitudinal Ultrasound, CT, MR modalities and extendable to 3D carotid Ultrasound. The on-line system consists of Atherosclerotic Wall Region estimation using AtheroEdge™ for longitudinal Ultrasound or Athero-CTView™ for CT or Athero-MRView from MR. This greyscale Wall Region is then fed to a feature extraction processor which uses the combination: (a) Higher Order Spectra; (b) Discrete Wavelet Transform (DWT); (c) Texture and (d) Wall Variability. Another combination uses: (a) Local Binary Pattern; (b) Law's Mask Energy and (c) Wall Variability. Another combination uses: (a) Trace Transform; (b) Fuzzy Grayscale Level Co-occurrence Matrix and (c) Wall Variability. The output of the Feature Processor is fed to the Classifier which is trained off-line.

The instant invention is drawn to methods and compositions useful for the assessment of cardiovascular risk in a mammal. The methods utilize biomarkers including prostanoid metabolites and isoprostanes as sensitive and stable markers of cardiovascular risk. The methods are particularly useful in a mammal that is contemplating undergoing coxib therapy, is undergoing coxib therapy, is undergoing antioxidant therapy, has ceased coxib therapy or has never undergone coxib therapy. The invention also includes kits useful for the assessment of cardiovascular risk in a mammal.

The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.

The invention generally provides compositions and methods of using a subject's genetic information for the selection of prophylactic or therapeutic agents and treatment regimens, and related methods for assaying the risk of an adverse cardiovascular event in the patient.

The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases.

Provided is a method for assessing cardiovascular risk in Metabolic Syndrome and Type 2 Diabetes patients. The method involves obtaining data from a Type 2 diabetes patient or a Metabolic Syndrome patient and determining a Fayad/Schentag index which includes a Glucose Supply Index (S) to an Insulin Demand Index (D) ratio. The Fayad/Schentag index is used in scoring cardiovascular risks of Metabolic Syndrome patients and for recommending and implementing therapeutic interventions that can be shown to lower cardiovascular risk

Macrophage migration inhibitory factor (MIF) is a clinically useful biochemical marker of cardiovascular risk. Risk assessment includes the step of detecting in the blood of a person MIF concentration as a marker of cardiovascular risk for the person. The method may further comprise the step of assigning to the person a cardiovascular risk metric proportional to the MIF concentration, and/or prescribing for the person a cardiovascular treatment modality in accordance with the MIF concentration. The method is useful as a primary screen, and may be used in conjunction with or as a substitute for additional tests, such as a stress test, CRP assay, LDL assay, etc. The detecting step may be repeated over time intervals and/or treatment to monitor change in cardiovascular risk for the person over time and/or treatment.

Health benefits from low n-6:n-3 fatty acid (FA) ratio on cardiovascular risk have been shown. However, the impact of the source of n-3 FAs has not been fully investigated. Our purpose was to investigate cardiovascular benefits of oils with a low ratio of n-6:n-3 FAs, but different sources of n-3 FAs. Mice were divided into 3 groups (n=7) and fed a diet supplemented with either a fish or flaxseed oil-based ‘designer oils’ with an approximate n-6:n-3 FA ratio of 2/1 or with a safflower-oil-based diet with a ratio of 25/1, for 16 weeks. Plasma lipids and fatty acid profile of the liver and heart tissues were characterized. Plasma cholesterol levels were reduced in both fish and flax groups by 27% and 36%, respectively, as compared to controls at endpoint. The levels of EPA and DHA in liver phospholipids were significantly increased in both fish and flax groups as compared to the control group, with more profound increases in the fish group. Arachidonic acid levels were similarly decreased in the liver tissues from both fish and flax groups as compared to controls. Our data indicates that health benefits may be achieved by lowering dietary n-6:n-3 FA even in a high fat diet medium.

Provided are methods for treating high cardiovascular risk patients with hypercholesterolemia and type 1 or type 2 diabetes mellitus receiving insulin therapy. These methods generally comprise administering to a patient a pharmaceutical composition comprising an antibody or antigen binding fragment, thereof, which specifically binds hPCSK9 antibody, in combination with insulin therapy.

A method (and the associated system) for risk evaluation in a vascular region of interest V are provided, making it possible, based on a fluidic study and/or on a treatment algorithm using a learning method, to generate risk models MR predictively indicating the risk level NR for the occurrence of events such as: occurrence and rupture of an aneurysm, coarctation, etc., and the associated anatomical areas. The models MR are intended to serve as an assistance support for the medical decision-making of a physician.

A digital cardiovascular risk evaluation system comprises an emergency vehicle terminal, a specialist terminal, a background terminal and a catheterization room terminal, all of which are connected by a mobile internet; the emergency vehicle terminal is bound with a mobile device, a client program installed on the mobile device can obtain patient data from a detector through a special interface so as to perform intelligent diagnosis and send the intelligent diagnosis to the background terminal by applying a consultation, and the background terminal saves and sends the intelligent diagnosis to the specialist terminal; a specialist guides on-vehicle doctors to rescue and performs judgment according to data sent by the specialist terminal; if the patient needs to directly enter a catheterization room without emergency treatment, the judgment is sent back the background terminal, the background terminal saves and sends the judgment to the emergency vehicle terminal, and meanwhile, the background terminal notifies that the catheterization room terminal prepares for interventional recanalization operation. Therefore, time is won for the patient, and the life of the patient is prolonged.

It is the object of a method and apparatus for retinal vessel analysis based on digital images to enhance the ability to discriminate between healthy vessel states and at-risk vessel states while reducing manual effort and saving time in order to allow individual vascular risk, particularly stroke risk, to be determined in a more reliable manner and with fewer subjective systematic and random errors. The vessel segment diameter, type of vessel and the image coordinates are determined for a series of adjoining vessel segments along vessel portions in a measurement zone surrounding the papilla and are stored by vessel segment with reference to the evaluated image, to a reference image recorded with a time offset, and to a displacement vector that is determined for the vessel segment between the reference image and an evaluated comparison image. Comparison measurements are carried out only on identical vessel segments already measured in the reference image. The correlation of vessel segments to vessel portions and to vessel type is adopted intact from the reference image. The stored data sets for the vessel segments of the reference image and comparison images provide a progression of coordinate-oriented vessel segment diameters for all measured vessel segments as basis for determining parameters and presenting them in a spatially resolved progression, e.g., in progress images.

The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk.

Provided are methods for treating high cardiovascular risk patients with hypercholesterolemia and type 1 or type 2 diabetes mellitus receiving insulin therapy. These methods generally comprise administering to a patient a pharmaceutical composition comprising an antibody or antigen binding fragment, thereof, which specifically binds hPCSK9 antibody, in combination with insulin therapy.

The present invention relates to a method for diagnosis of a cardiovascular disease or condition or atherosclerosis and for a method for evaluating the risk of a subject of developing the same. Methods are further provided for evaluating a subject's risk of mortality, for evaluating whether a subject will benefit from a certain treatment or whether a subject needs to be hospitalized or whether a subject may be discharged. The present invention provides sCD14 or a fragment or derivative thereof (including in particular sCD14-ST) as a novel marker for cardiovascular risk in general, more specifically as a marker for cardiovascular disease or condition, or atherosclerosis.